Used in cancer immunotherapy to block the CD47 "don't eat me" signal on tumor cells, enabling macrophages and other immune cells to recognize and destroy cancer cells. Investigated in clinical trials for hematologic malignancies such as acute myeloid leukemia and non-Hodgkin lymphoma, as well as solid tumors. Enhances phagocytosis when combined with tumor-targeting antibodies, supporting potential combination therapies. Also explored for its role in modulating the tumor microenvironment to improve immune response.